Last Updated: November 8, 2026

CLINICAL TRIALS PROFILE FOR CYTADREN

« Back to Dashboard

All Clinical Trials for CYTADREN

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00006371 ↗	A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer	Terminated	Janssen Pharmaceuticals	Phase 2	2000-05-01	RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as aminoglutethimide or ketoconazole may stop the adrenal glands from producing hormones. Combining hydrocortisone with either aminoglutethimide or ketoconazole may be an effective treatment for prostate cancer. PURPOSE: Phase II trial to study the effectiveness of combining hydrocortisone with either aminoglutethimide or ketoconazole in treating patients who have localized stage IV prostate cancer.
NCT00006371 ↗	A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer	Terminated	National Cancer Institute (NCI)	Phase 2	2000-05-01	RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as aminoglutethimide or ketoconazole may stop the adrenal glands from producing hormones. Combining hydrocortisone with either aminoglutethimide or ketoconazole may be an effective treatment for prostate cancer. PURPOSE: Phase II trial to study the effectiveness of combining hydrocortisone with either aminoglutethimide or ketoconazole in treating patients who have localized stage IV prostate cancer.
NCT00006371 ↗	A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer	Terminated	H. Lee Moffitt Cancer Center and Research Institute	Phase 2	2000-05-01	RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as aminoglutethimide or ketoconazole may stop the adrenal glands from producing hormones. Combining hydrocortisone with either aminoglutethimide or ketoconazole may be an effective treatment for prostate cancer. PURPOSE: Phase II trial to study the effectiveness of combining hydrocortisone with either aminoglutethimide or ketoconazole in treating patients who have localized stage IV prostate cancer.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for CYTADREN

Condition Name

Chart
Table

Condition Name for CYTADREN
Intervention	Trials
Prostate Cancer	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for CYTADREN
Intervention	Trials
Prostatic Neoplasms	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for CYTADREN

Trials by Country

Map
Table

Trials by Country for CYTADREN
Location	Trials
United States	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for CYTADREN
Location	Trials
Florida	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for CYTADREN

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for CYTADREN
Clinical Trial Phase	Trials
Phase 2	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for CYTADREN
Clinical Trial Phase	Trials
Terminated	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CYTADREN

Sponsor Name

Chart
Table

Sponsor Name for CYTADREN
Sponsor	Trials
Janssen Pharmaceuticals	1
National Cancer Institute (NCI)	1
H. Lee Moffitt Cancer Center and Research Institute	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for CYTADREN
Sponsor	Trials
Industry	1
NIH	1
Other	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.